A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
WHO International Clinical Trials Registry Platform - (2022) vom: 02. Mai Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Unbestimmt |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 16-11-2021, Last updated: 2022-11-24 |
---|
ICTRP ID: |
EUCTR2021-000044-22-DE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
WHO008166102 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | WHO008166102 | ||
003 | DE-627 | ||
005 | 20230425182829.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220203s2022 xx |||||o 00| ||und c | ||
035 | |a (DE-627)WHO008166102 | ||
035 | |a (UBBS_Klinische_Studien_WHO)EUCTR2021-000044-22-DE | ||
035 | |a (UBBS_Klinische_Studien_WHO)C1071005 | ||
035 | |a (UBBS_Klinische_Studien_WHO)NCT05020236 | ||
035 | |a (UBBS_Klinische_Studien_WHO)2021-000044-22-SE | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a und | ||
245 | 1 | 0 | |a A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |b AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 16-11-2021, Last updated: 2022-11-24 | ||
650 | 4 | |a Medical Condition: MULTIPLE MYELOMA MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04] | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Phase: Phase 3 | |
650 | 4 | |a Recruitment Status: Authorised-recruitment may be ongoing or finished | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2022) vom: 02. Mai |
773 | 1 | 8 | |g year:2022 |g day:02 |g month:05 |
856 | 4 | 0 | |u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000044-22 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2022 |b 02 |c 05 |